BioNexus Gene Lab Corp.
BGLC
$5.30
-$0.12-2.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.55M | 9.27M | 9.51M | 9.26M | 9.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.55M | 9.27M | 9.51M | 9.26M | 9.18M |
| Cost of Revenue | 8.20M | 8.00M | 8.22M | 8.01M | 7.91M |
| Gross Profit | 1.35M | 1.27M | 1.29M | 1.25M | 1.27M |
| SG&A Expenses | 3.80M | 2.88M | 2.49M | 2.76M | 3.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 702.00K | 760.40K | 748.50K | -56.20K | 210.00K |
| Total Operating Expenses | 12.77M | 11.71M | 11.53M | 10.79M | 11.90M |
| Operating Income | -3.22M | -2.44M | -2.02M | -1.53M | -2.72M |
| Income Before Tax | -3.01M | -2.13M | -1.59M | -919.20K | -2.11M |
| Income Tax Expenses | -72.10K | -16.50K | 3.60K | 22.40K | 97.20K |
| Earnings from Continuing Operations | -2.93 | -2.12 | -1.60 | -0.94 | -2.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.93M | -2.12M | -1.60M | -941.60K | -2.21M |
| EBIT | -3.22M | -2.44M | -2.02M | -1.53M | -2.72M |
| EBITDA | -3.11M | -2.33M | -1.92M | -1.44M | -2.64M |
| EPS Basic | -1.63 | -1.18 | -0.89 | -0.52 | -1.33 |
| Normalized Basic EPS | -1.03 | -0.75 | -0.60 | -0.46 | -0.94 |
| EPS Diluted | -1.63 | -1.18 | -0.89 | -0.52 | -1.33 |
| Normalized Diluted EPS | -1.03 | -0.75 | -0.60 | -0.46 | -0.94 |
| Average Basic Shares Outstanding | 7.19M | 7.16M | 7.13M | 7.11M | 6.99M |
| Average Diluted Shares Outstanding | 7.19M | 7.16M | 7.13M | 7.11M | 6.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |